Patents Assigned to Merck
  • PRMT5 INHIBITORS
    Publication number: 20210309688
    Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
    Type: Application
    Filed: August 5, 2019
    Publication date: October 7, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Michelle Machacek, Michael H. Reutershan, Sebastian Schneider
  • Binuclear metal complexes for use as emitters in organic electroluminescent devices
    Patent number: 11136343
    Abstract: The present invention relates to binuclear metal complexes and electronic devices, in particular organic electroluminescent devices containing said metal complexes.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: October 5, 2021
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Christian Ehrenreich, Philipp Harbach, Anna Hayer, Esther Breuning
  • Optical device comprising a switchable layer and at least one optical layer
    Patent number: 11137639
    Abstract: The invention relates to a switchable optical device (10) having a layer structure comprising at least one switchable layer (15) and at least one optical layer (20, 22). The at least one switchable layer (15) comprises a liquid-crystalline material and at least one dye. The at least one optical layer (20, 22) has at least one reflection band (32) which includes at least a first part of the visible spectrum and has at least one transmission band (30, 34) which includes at least a second part of the visible spectrum. The absorption spectrum of the at least one switchable layer (15) is adjusted by means of the at least one dye such that the light transmission through the switchable optical device (10) for incident light in the visible light spectrum for at least one of the states of the switchable layer (15) is set to a predetermined transmission spectrum.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: October 5, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Ties De Jong, Casper Van Oosten
  • TLR7/8 ANTAGONISTS AND USES THEREOF
    Publication number: 20210300940
    Abstract: Compounds of Formula (I) and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Application
    Filed: July 29, 2019
    Publication date: September 30, 2021
    Applicant: Merck Patent GmbH
    Inventors: Brian Sherer, Ruoxi Lan, Nadia Brugger, Xiaoling Chen, Momar Toure, Esther Cleary, Lizbeth Celeste Deselm, Yanping Wang
  • STABLE FORMULATIONS OF CYTOMEGALOVIRUS
    Publication number: 20210299247
    Abstract: The present invention relates to stable formulations of a cytomegalovirus (CMV) comprising for example, a genetically modified CMV that is conditionally replication defective, a buffer, alkali or alkaline salt, a sugar, a cellulose derivative and optionally a polyol.
    Type: Application
    Filed: October 29, 2018
    Publication date: September 30, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Muneeswara Babu Medi, Harrison Bradford Davis, Lorenzo H. Chen, Lynne Ann Isopi, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler
  • Transglutamine tag for efficient site-specific bioconjugation
    Patent number: 11130818
    Abstract: The present invention provides novel peptide sequences for use in microbial transgluatminase-mediated, in particular mTG2-mediated bioconjugations, in particular for the manufacture of antibody-drug-conjugates. Further disclosed are bioconjugation methods employing mTG2 and the novel peptide sequence motifs of the invention. The present invention further provides proteins comprising the novel sequence motifs of the invention as well as polynucleotides encoding the same.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: September 28, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Birgit Piater, Ulrich Betz, Harald Kolmar, Vanessa Siegmund
  • Anti-lap antibody variants
    Patent number: 11130802
    Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: September 28, 2021
    Assignees: Tilos Therapeutics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Randall Burton, Jessie M. English, Barbara S. Fox, Stavros Kopsiaftis, Renee Moore, Patricia Rao, Kenneth J. Simon
  • ELECTRONIC SWITCHING ELEMENT
    Publication number: 20210292651
    Abstract: An electronic switching element is described having, in sequence, a first electrode, a molecular layer bonded to a substrate, and a second electrode. The molecular layer contains compounds of formula I, R1-(A1-Z1)r—B1—(Z2-A2)s-Sp-G, wherein A1, A2, B1, Z1, Z2, Sp, G, r, and s are as defined herein, in which a mesogenic radical is bonded to the substrate via a spacer group, Sp, by means of an anchor group, G. The switching element is suitable for production of components that can operate as a memristive device for digital information storage.
    Type: Application
    Filed: June 7, 2021
    Publication date: September 23, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Peer KIRSCH, Andreas RUHL, Marc TORNOW, Achyut BORA
  • LIGHT LUMINESCENT PARTICLE
    Publication number: 20210292644
    Abstract: The present invention relates to a light luminescent particle, use of the light luminescent particle and method for preparation of the light luminescent particle. The present invention further relates to composition, an optical medium, and an optical device and method for preparation of thereof.
    Type: Application
    Filed: September 7, 2017
    Publication date: September 23, 2021
    Applicant: Merck Patent GmbH
    Inventor: Arjan MEIJER
  • LIQUID CRYSTAL MIXTURE AND LIQUID CRYSTAL DISPLAY
    Publication number: 20210292652
    Abstract: The invention relates to a compound of formula I, R11, R21, A11, A, Z, X11, X21, Y11, Y12, Sp11, Sp21, o and p have one of the meanings as given in claim 1. The invention further relates to method of production of a compound of formula I, to the use of said compounds in LC media and to LC media comprising one or more compounds of formula I. Further, the invention relates to a method of production of such LC media, to the use of such media in LC devices, and to LC device comprising a LC medium according to the present invention. The present invention further relates to a process for the fabrication such liquid crystal display and to the use of the liquid crystal mixtures according to the invention for the fabrication of such liquid crystal display.
    Type: Application
    Filed: April 18, 2019
    Publication date: September 23, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Lars LIETZAU, Simon SIEMIANOWSKI, Izumi SAITO
  • A VIRUS NEUTRALIZATION ASSAY UTILIZING IMAGING CYTOMETRY
    Publication number: 20210293818
    Abstract: The instant invention describes a virus reduction neutralization test (VRNT) which is a rapid, high throughput alternative to current standard low throughput and laborious neutralization assays. The VRNT utilizes imaging cytometry to count virus-infected cells at about one day post-infection (thus eliminating the wait time other assays employ allowing for viral infection cell to cell), reducing overall assay time and increasing throughput at least 15-fold.
    Type: Application
    Filed: August 9, 2019
    Publication date: September 23, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Melissa C. Whiteman, Joseph M. Antonello, Leah A. Bogardus, Danila G. Giacone, Dengyun Sun, Amy H.M. Tou, Kevin B. Gurney, Leonard J. Rubinstein
  • FORMULATIONS OF RALTEGRAVIR
    Publication number: 20210290548
    Abstract: The present invention is directed to compressed tablets for oral administration, which comprise an intragranular component comprising the potassium salt of raltegravir, an inert superdisintegrant, and a binder; and an extragranular component comprising a superdisintegrant and a lubricant.
    Type: Application
    Filed: May 31, 2019
    Publication date: September 23, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Majid Mahjour, Ronald L. Smith
  • Antiviral benzyl-amine phosphodiamide compounds
    Patent number: 11123355
    Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: September 21, 2021
    Assignees: Idenix Pharmaceuticals LLC, Merck Sharp & Dohme Corp.
    Inventors: Manuel de Lera Ruiz, Timothy J. Hartingh, Izzat Raheem, John Schreier, Jean-Laurent Paparin
  • Light modulation element
    Patent number: 11124705
    Abstract: The invention relates to a light modulation element comprising a pair of substrates, one or more optical films located on the inner side of one of the substrates, an electrode structure capable of inducing an electric field substantially in parallel to the substrates main plane, and a homogenously aligned liquid crystalline medium which is obtainable from a photoalignment component A) and a liquid-crystalline component B). Furthermore, the invention relates process of production of the light modulation element, to the use of the light modulation element in an electro optical device and to an electro optical device comprising said light modulation element.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: September 21, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Phil Baker, Rachel Tuffin, Joseph Sargent, Ian Sage
  • Process for making beta 3 agonists and intermediates
    Patent number: 11124478
    Abstract: The present invention is directed to a process for preparing a compound of formula I-11 through multiple-step reactions:
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: September 21, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Prefilled disposable injection device
    Patent number: 11123499
    Abstract: The present invention relates to drug delivery systems that cannot be reloaded or reused and further include a passive safety shield system. The drug delivery devices described herein include a drug container comprising at least one bellow, a needle, wherein the needle is in liquid communication with the drug container; a plunger extending between a proximal end and a distal end, wherein the plunger is in communication with the drug container and where upon axial movement of the plunger, the drug container is compressed.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: September 21, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter A. Basile, Steven Carl Persak, Mikhail Gotliboym, Brad Britland, Stephen G. Miggels, Henry J. Mack, Jr., Oliver J. Sha
  • METHOD FOR PRODUCING AN ELECTRONIC DEVICE
    Publication number: 20210284812
    Abstract: The present application relates to a method for producing a polycycloolefin layer, to electronic devices produced by such method and comprising such layer as well as to formulations used for making such polycycloolefin layer.
    Type: Application
    Filed: June 25, 2019
    Publication date: September 16, 2021
    Applicant: Merck Patent GmbH
    Inventors: Holger HEIL, Matthias KOCH, Nathan SMITH
  • LIQUID CRYSTAL MIXTURE AND LIQUID CRYSTAL DISPLAY
    Publication number: 20210284912
    Abstract: The invention relates to a compound of formula I, wherein R11, R21, A11, A, Z, X11, X21, Y11, Y12, Sp11, Sp21, o and p have one of the meanings as given in claim 1. The invention further relates to method of production of a compound of formula I, to the use of said compounds in LC media and to LC media comprising one or more compounds of formula I. Further, the invention relates to a method of production of such LC media, to the use of such media in LC devices, and to LC device comprising a LC medium according to the present invention. The present invention further relates to a process for the fabrication such liquid crystal display and to the use of the liquid crystal mixtures according to the invention for the fabrication of such liquid crystal display.
    Type: Application
    Filed: April 18, 2019
    Publication date: September 16, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Lars LIETZAU, Simon SIEMIANOWSKI, Izumi SAITO, Rocco FORTTE
  • Electro-Optical Display Elements
    Publication number: 20210284911
    Abstract: An electro-optical display element in the areas of displays for watches, pocket calculators, large display panels as used in railway stations, airports and sports arenas, displays of portable or desktop computers, navigation systems and video applications, which upon the application of a voltage to the display element achieves that the longitudinal axis of molecules in a liquid-crystalline media orients itself in such a way that the larger of the dielectric constants becomes effective, which electro-optical display element contains two plates of a capacitor.
    Type: Application
    Filed: February 5, 2021
    Publication date: September 16, 2021
    Applicant: Merck Patent GmbH
    Inventors: Volker Reiffenrath, Matthias Bremer, Rocco Fortte, Harald Hirschmann, Martin Engel
  • CRYSTALLINE SALTS OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND L-LEUCINE ETHYL ESTER
    Publication number: 20210283136
    Abstract: The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.
    Type: Application
    Filed: July 2, 2019
    Publication date: September 16, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Rudolf MOSER, Viola GROEHN, Ruth BOEHNI STAMM, Fritz BLATTER, Martin SZELAGIEWICZ